Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00748657 · OUTCOME

Overall Survival

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
From study entry to death or last contact, up to 5 years.

What was measured

The observed length of life from entry into the study to death or the date of last contact.

Analysis population: Eligible and treated patients.

Groups in this outcome

Bevacizumab

Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab36

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
BevacizumabNANot reported44.9NANA (not available): median OS was not reached but is \>65.9 months, as is the upper bound of the 95% CI.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA (not available): median OS was not reached but is \>65.9 months, as is the upper bound of the 95% CI.
        group Id
        OG000
        lower Limit
        44.9
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
The observed length of life from entry into the study to death or the date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment
    id
    OG000
    title
    Bevacizumab
param Type
MEDIAN
population Description
Eligible and treated patients.
reporting Status
POSTED
time Frame
From study entry to death or last contact, up to 5 years.
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice